FY sales rose 12% (organic: +3%) to €46,324m and the gross profit margin significantly improved by 2.5bp to 54.3%. EBITDA went up +15% to €9,583m and earnings attributable to shareholders climbed +20% to €4,110m. Operating CF strongly rose +19% to €6,847m accelerated by NWC’s improvement (€-152m after €-1,010m), primarily driven by a weaker inventory build-up. The previous year’s investing CF was characterised by the acquisition of the OTC business fr
25 Feb 2016
Marijn’s large footsteps
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Marijn’s large footsteps
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
25 Feb 2016 -
Author:
Martin Schnee -
Pages:
3
FY sales rose 12% (organic: +3%) to €46,324m and the gross profit margin significantly improved by 2.5bp to 54.3%. EBITDA went up +15% to €9,583m and earnings attributable to shareholders climbed +20% to €4,110m. Operating CF strongly rose +19% to €6,847m accelerated by NWC’s improvement (€-152m after €-1,010m), primarily driven by a weaker inventory build-up. The previous year’s investing CF was characterised by the acquisition of the OTC business fr